Emmes is excited to share the significant progress being made in clinical studies.
We also give you a look inside some of our own news.
Research on traumatic brain injury in the military highlighted in Undersea and Hyperbaric Medicine Journal
Company News
<p>The Emmes Corporation today announced that a large team of scientists and health professionals including those from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have authored a series of papers summarizing significant research on traumatic brain injury in the military. </p><p>Dr. Anne Lindblad, biostatistician and Emmes president and chief executive officer, and Dr. Steffanie Wilson, Emmes biostatistician, collaborated with principal investigator Dr. Lindell Weaver of the Hyperbaric Medicine Department of LDS Hospital, as well as Susan Churchill and Kayla Deru, also of LDS Hospital. Representing the funding organization of the study, the Hyperbaric Oxygen Project Management Office of the U.S. Army Medical and Materiel Development Activity, were Col. Scott Miller, Col. Austin Chhoeu, Capt. Brett Hart and Capt. Leonard Skipper. </p><p>According to Dr. Weaver of LDS Hospital, “These papers addressed the baseline findings of one of the most complex clinical trials of hyperbaric oxygen, which is being investigated as a potential intervention for post‐concussive symptoms following mild traumatic brain injury in a military population.” The study, sponsored by the Department of Defense, addressed both active duty and veterans in the military who suffered from mild traumatic brain injuries. </p><p>He added, “Even though our study was directed to military personnel, its results will be applicable to people outside the military, such as victims of sports injuries and car accidents who have suffered from mild traumatic brain injuries.” </p><p>Hyperbaric oxygen therapy is often associated with the treatment for carbon monoxide poisoning, as well as decompression sickness, which can result from scuba diving. Under hyperbaric oxygen therapy, a person inhales 100 percent oxygen in a total body chamber. </p><p>Dr. Wilson of Emmes explained that this study differed from those in the past both in duration of follow‐up activities with the participants and a more comprehensive battery of assessments in such groups as visual, audiological, neurological, neuropsychological and neuroimaging. “A key purpose of our research was to understand how the study population performed on these assessments to help select endpoints for related clinical trials in the future,” she said. </p><p>“The papers we wrote for the Undersea and Hyperbaric Medicine Journal addressed baseline data from the clinical trial,” she continued. “We appreciate the combined efforts of the study team and all of the authors of the papers. We expect to produce a series of additional manuscripts on post‐intervention findings.” </p><p>Dr. Lindblad, president and chief executive officer of Emmes, said, “We hope this research will be the cornerstone of an expanded opportunity for exploring more effective treatment for brain injuries and potentially post‐traumatic stress disorder. This is a perfect example of the benefits of scientific collaboration.” </p><p><strong>About the Research</strong><br />The papers were published in a special edition of the <a href="https://www.uhms.org/publications/uhm-journal/purchase-uhm-journal-v43-… and Hyperbaric Medicine Journal</a> this month. Non‐subscribers can access the papers for a nominal fee. </p><p><strong>About Emmes</strong><br />We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com. </p>
Dr. Paul VanVeldhuisen Named Chief Operating Officer of The Emmes Corporation
Company News
<p>The Emmes Corporation today announced that Dr. Paul VanVeldhuisen has been promoted to the newly created position of chief operating officer. Dr. VanVeldhuisen, who started at Emmes as a statistician and epidemiologist, will assume the additional leadership responsibilities while continuing to serve as principal investigator for government and privately funded research projects. </p>
<p>Dr. VanVeldhuisen joined the company in 1993 and was promoted to vice president in 2006. He is responsible for the scientific aspects of various research studies, including study design and analysis, and he oversees day-to-day operations of clinical trial support. Dr. VanVeldhuisen has contributed to research in important public health areas, including ophthalmology, drug abuse, organ transplantation and infectious disease. He also received the company’s Public Health Impact Award in 2013 for his team’s research on the safety of cesarean sections.</p>
<p>“I’m looking forward to my new role,” noted Dr. VanVeldhuisen. “What has stayed consistent during my 22 years here is our commitment to provide critical services that address important issues in public health. We’re involved in long-term studies on childhood cancer, clinical trials of HIV vaccines, vaccine trials associated with a pandemic threat, studies aimed at preventing and treating vision loss, and research in real-world settings examining prevention and treatment of substance use. These are the kinds of challenges that inspire our staff to do their best. It’s the dedicated employees committed to Emmes’ mission that make this a remarkable place to work.”</p>
Research Shows Lithium as an Effective Treatment for Pediatric Bipolar Disorder
Company News
<p>The Emmes Corporation today announced that three of its statisticians, Dr. Ravinder Anand, Dr. Traci Clemons and Karen Martz, co-authored a pivotal study that examined lithium as a treatment for pediatric bipolar I disorder. The study was published in the October issue of Pediatrics.</p>
Emmes Recognized in New Research Published by the Journal of the American Medical Association
Company News
<p>The Emmes Corporation today announced that one of its principal investigators and statisticians, Dr. Traci Clemons, co-authored a study that was just published by the Journal of the American Medical Association (JAMA). The researchers had conducted a five-year study with 4,000 patients to determine whether omega-3 and other nutritional supplements are associated with cognitive function. Dr. Clemons had led the Emmes team doing the clinical trials associated with the study.</p>
Emmes Announces FDA Clearance of New Medical Device
Company News
<p>The New "Mercy TAPE" Estimates Pediatric Weight with Greater Accuracy, Giving Doctors a Better Tool for Determining Prescription Dosage.<br />
The Emmes Corporation today announced that the U.S. Food and Drug Administration (FDA) has given marketing clearance for a new device that allows doctors to more accurately assess children’s weight without the use of a weight scale. Weight estimates are used in emergency situations and in developing countries where scales may not be available. This new device will allow doctors to determine with greater accuracy the prescription dosage levels needed for children with a range of illnesses and across a variety of settings throughout the world.</p>
EMMES to Coordinate NCI Anal Cancer Prevention Study
Company News
<p>With the support of The EMMES Corporation, clinical investigators from the AIDS Malignancy Consortium (AMC) are preparing to enroll HIV-infected men and women throughout the United States and Puerto Rico in a major investigation of a prevention strategy for anal cancer. The study will enroll over 5,000 participants who are HIV-infected and who have pre-cancerous lesions. EMMES will provide operations, data management, site monitoring, and regulatory support under the eight-year, $89 million award. The study is scheduled to begin enrollment this month.</p>
EMMES Wins IDIQ Contract
Company News
<p>Under the contract, EMMES will provide a full range of services that support public health emergency preparedness. These include statistical expertise and project management, study design and protocol development, data collection, and data analysis and reporting. In addition, the company will also provide enhanced safety reporting through its pharmacovigilence program with both Emergency Medicine and Infectious Disease expertise and will manage a large team of subcontractors at laboratories and sites across the country. The two-year contract, which includes three one-year options, has a ceiling of $100 million. EMMES was one of five companies selected to compete for services under this IDIQ contract.</p>
New research firm CEO never stops learning
Company News
<p>When she was young, Anne Lindblad was interested in medicine, even becoming a physician, until she came face-to-face with the inevitable frog to dissect in high school biology class. “I mutilated that frog,” recalled Lindblad, who recently was promoted to CEO and president of The Emmes Corp., a Rockville research company that conducts studies for clinicians and biomedical scientists. “That dashed my hopes of becoming a physician.” But math was another of her likes, and after growing up in Cleveland, Ohio, she enrolled at Hollins University in Roanoke, Va. “It was one of the few colleges in the area that offered a degree in statistics back then,” Lindblad said. After earning a statistics degree there, she went to the Medical College of Virginia in Richmond and obtained a master’s in biostatistics. She started teaching at the all-girls Foxcroft School in Middleburg, Va., where she began a statistics course. While in graduate school, Lindblad met Donald Stablein, who earned a doctorate in biostatistics from the Medical College of Virginia and started working for Emmes as a staff statistician in 1980, some three years after the company formed. Stablein eventually became president of Emmes. “We kept in contact, and he asked me if I wanted a job,” said Lindblad, who earned a doctorate herself in statistics from George Washington University. She joined Emmes in 1982 and worked her way to vice president in 1992 and executive vice president in 2006. She has led major projects in ophthalmology, oncology, transplantation, neurology, stroke, traumatic brain injury and more. “I’m in a field where you never stop learning,” Lindblad said.</p>
EMMES Renews Lease
Company News
<p>The EMMES Corporation today announced that it has signed a 10-year lease that gives the company expanded office space at its current headquarters at 401 North Washington Street in Rockville’s town center. The lease totals 97,000 square feet.<br />“Our new lease signals the next chapter of success for the company,” said Dr. Anne Lindblad, executive vice president of EMMES. “We have built a reputation as a trusted partner to researchers who are dedicated to developing better treatments for patients. We’re proud of our 35-year history, and we’re optimistic about our future opportunities.”<br />Brian Hochheimer, EMMES vice president and chief financial officer, added, “The new lease supports our growth and hiring plans. It gives us four full floors and represents nearly a three-fold expansion compared to the square footage of our original lease. We love being right in the center of Rockville, and we’re pleased to continue the relationship with our landlord, 401 North Washington LLC.”<br />According to Isiah Leggett, Montgomery County executive, “We’re thrilled that EMMES has decided to remain in Rockville, the third largest city in Maryland and a robust business center. EMMES has been a pillar of our local economy, creating and sustaining jobs that contribute to the improvement of public health. The company offers scientific, technology and research services and has a highly educated employee base.”<br />Phyllis Marcuccio, Rockville mayor, noted, "We are delighted that EMMES, one of our major employers, has elected not only to remain in our city, but to enlarge and upgrade its space. The City of Rockville<br />looks forward to working with and supporting the company as it continues to contribute to the life sciences industry cluster here."<br />Leggett added, “With the signing of the new lease, EMMES remains close to the campus of one of its major customers, the National Institutes of Health. Company executives cited the outstanding location in Rockville Town Center, proximity to public transportation and the excellent educational offerings at the Universities at Shady Grove as key reasons for maintaining its headquarters in our county.”<br />EMMES was represented by Larry Bank and Lisa Benjamin of Newmark Grubb Knight Frank in the transaction.</p>
Anne Lindblad Promoted to President/CEO of The EMMES Corporation
Company News
Dr. Lindblad is a biostatistician with experience in clinical design and project management. Lindblad joined EMMES in 1982 and became vice president in 1992 and executive vice president in 2006. During her 30-year career at EMMES, she has led major projects in ophthalmology, oncology, nephrology, transplantation, neurology, stroke, traumatic brain injury, dental disease and swallowing disorders. She has served as a reviewer of grant and contract applications for the National Institutes of Health and has chaired or served on Data and Safety Monitoring Committees in multiple disease areas. In addition, she has served on the board of directors and as president of the Society for Clinical Trials, as well as the clinical trials section editor for JAMA Ophthalmology, formerly the Archives of Ophthalmology. Lindblad has authored or co-authored more than 100 publications and presentations. She holds a Ph.D. in statistics from the George Washington University, a master’s degree in biostatistics from the Medical College of Virginia, and a bachelor’s degree in Statistics from Hollins College. Lindblad lives in Middleburg, Virginia, with her husband and two daughters.
